H Fukumoto

Summary

Affiliation: Pharmaceutical Research Division
Country: Japan

Publications

  1. ncbi The novel compound TDN-345 induces synthesis/secretion of nerve growth factor in C6-10A glioma cells
    H Fukumoto
    Pharmaceutical Research Laboratories I, Takeda Chemical Ind Ltd, Osaka, Japan
    Brain Res 774:87-93. 1997
  2. ncbi A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease
    Hiroaki Fukumoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Yodogawa ku, Osaka 532 8686, Japan
    J Neurosci 30:11157-66. 2010

Detail Information

Publications2

  1. ncbi The novel compound TDN-345 induces synthesis/secretion of nerve growth factor in C6-10A glioma cells
    H Fukumoto
    Pharmaceutical Research Laboratories I, Takeda Chemical Ind Ltd, Osaka, Japan
    Brain Res 774:87-93. 1997
    ..The results of the present study suggest the existence of a signal transduction pathway for NGF synthesis/secretion which is not mediated by cAMP...
  2. ncbi A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease
    Hiroaki Fukumoto
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Yodogawa ku, Osaka 532 8686, Japan
    J Neurosci 30:11157-66. 2010
    ..These results support the feasibility of BACE1 inhibition with a noncompetitive inhibitor as disease-modifying as well as symptomatic therapy for AD...